NAYA Biosciences Announces Development Of NY-500 Novel AI-Optimized PD-1 X VEGF Bifunctional Antibody

NAYA Biosciences, Inc. - Common Stock 0.00%

NAYA Biosciences, Inc. - Common Stock

NAYA

0.36

0.00%

  PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications

•  NAYA aiming to initiate clinical trials in early 2026

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via